Study of corneal cells after a ranibizumab eye implant
Treatments studied
Part of Eyes & vision clinical trials.
This trial checks how well corneal endothelial cells (cells that help keep the cornea clear) do in people with neovascular age-related macular degeneration (nAMD) who are treated with a port-delivery implant that releases ranibizumab. It also helps doctors understand whether this method changes corneal health and stays safe while controlling the eye disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with neovascular age-related macular degeneration (nAMD) before screening.
- Your two eyes should be similar in corneal cell density, with less than 10% difference between eyes (measured by a cornea cell scan).
- You can provide past vision test results and eye scans (OCT), and you have detailed past records of anti-VEGF injections (what medicine and when).
- You must have been treated with at least two anti-VEGF injections in the past and had a good response (less disease activity on scan and stable or better vision).
- Your clearest corrected vision should be about 20/200 (ETDRS 34 letters) or better at screening.
- You must have a clear cornea enough for the study team’s reading center to analyze cornea cell images and eye scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether continuing treatment with a refillable eye implant (Port Delivery System) and ranibizumab injection helps control a specific type of wet macular degeneration. It’s mainly for people who already finished an earlier related study and are able to keep up with frequent eye checks and procedures.
This trial tests a one-time gene therapy injection for wet AMD that may reduce the need for regular eye injections. It is for people who have already responded to anti-VEGF injections but want a longer-lasting treatment.
This Phase 3 study tests whether a small eye implant that delivers medicine on a schedule (the port delivery system) with ranibizumab works better and safely in people with wet age-related macular degeneration. It’s designed for patients who have already been treated recently with anti-VEGF injections and need continued control.
This trial tests a refillable eye implant (PDS) that slowly releases medication to treat wet age-related macular degeneration (nAMD). It aims to see if replacing the implant every 36 weeks works as well as regular eye injections.
This study tests a new medicine called IBI302 for wet age-related macular degeneration (AMD). It aims to slow vision loss by targeting both blood vessel growth and inflammation. You might qualify if you have active wet AMD and have not had certain injections recently.
This study tests whether a new eye injection called ABP 938 works as well as or better than the current standard treatment (Eylea) for wet age-related macular degeneration—a condition that causes vision loss in the center of your sight. You would receive injections into your eye every month for a year.
Hear when a new Neovascular Age-related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.